Lisdexamphetamine tied with improved outcomes for those with amphetamine disorders

Results:

There were 13 965 individuals in the cohort.

• During follow-up, 7543 individuals (54.0%) were taking antidepressants, 6101 (43.7%) benzodiazepines, 5067 (36.3%) antipsychotics, 3941 (28.2%) ADHD medications (1511 [10.8%] were taking lisdexamphetamine), 2856 (20.5%) SUD medications, and 1706 (12.2%) mood stabilizers.

• A total of 10 341 patients (74.0%) were hospitalized due to SUDs, 11 492 patients (82.3%) were hospitalized due to any cause or died, and 1321 patients (9.5%) died of any cause.

• Lisdexamphetamine was the only medication in this study that was significantly associated with a decrease in risk of 3 outcomes

• Methylphenidate use also was associated with lower all-cause mortality

• Use of benzodiazepines was associated with a significantly higher risk of SUD hospitalization, any hospitalization or death, and all-cause mortality

• Use of antidepressants or antipsychotics was associated with a slight increase in risk of SUD hospitalization as well as any hospitalization or death

In this study, use of lisdexamphetamine was associated with improved outcomes in persons with amphetamine or methamphetamine use disorders, encouraging the conduct of randomized clinical trials. Prescription benzodiazepine use was associated with poor outcome.

Reference:

Heikkinen M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, Lähteenvuo M, Tiihonen J. Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients. JAMA Psychiatry. Published online November 16, 2022. doi:10.1001/jamapsychiatry.2022.3788